Upload Avatar (500 x 500)
Jun Jie Xu
walter235@zju.edu.cn
English, Chinese
Zhejiang
Zhejiang University
Medical
  • 2019/03-2022/03 Clinical Medicine Postdoc: Zhejiang University, Supervisor: Xiu Jun Cai
  • 2013/09-2018/06 Minimally Invasive Medicine PhD: Zhejiang University, Supervisor: Xiu Jun Cai
  • 2014/03-2015/07 Visiting Scholar: University of Rochester Medical Center
  • 2008/09-2013/06 Clinical Medicine Bachelor's: Shanghai Jiao Tong University
  • Published over 30 SCI papers with more than 1500 citations
  • H-index of 21 on Google Scholar
  • First or corresponding author of 23 SCI papers
  • 2022/12-Present - Zhejiang University School of Medicine - Distinguished Researcher
  • 2022/07-Present - Zhejiang University School of Medicine Affiliated Sir Run Run Shaw Hospital - Assistant Director of Research Office
  • 2022/06-Present - Zhejiang University School of Medicine - Deputy Director of Research Office (Concurrent)
  • 2021/03-2022/02 - National Natural Science Foundation of China Medical Science Department - Part-time
  • 2019/07-Present - Zhejiang University School of Medicine Affiliated Sir Run Run Shaw Hospital - Attending Physician
  • 2018/08-2019/06 - Zhejiang University School of Medicine Affiliated Sir Run Run Shaw Hospital - Resident Physician
  • 2018/07-2018/08 - University of Hong Kong Mary Hospital - Clinical Visiting Scholar
  • Zhejiang Province Ten Thousand Talents Program Young Top Talent
  • Member of EASL, AASLD, CSCO
  • Committee Member of the Hepatobiliary Branch of the Chinese Medical Association of European and American Alumni Association
Minimally invasive precision diagnosis and treatment of malignant tumors of the liver and gallbladder
Mechanisms and translational research of drug resistance and metastasis of malignant tumors of the liver and gallbladder
Immune metabolic microenvironment of liver cancer
  • Sig Transduct Target Ther (2020 Cover Article, 2021 Cover Article/Highly Cited Paper, IF: 38.104), Jun Jie Xu, 2020
  • Mol Cancer (2020, IF: 41.444), Jun Jie Xu, 2020
  • EBioMedicine (2016, 2020, IF: 11.205), Jun Jie Xu, 2020
  • Am J Gastroenterol (2021, IF: 12.045), Jun Jie Xu, 2021
  • Cancer Letters (2024, IF: 9.7), Jun Jie Xu, 2024
  • Cell Mol Gastroenterol Hepatol (2021, IF: 9.225), Jun Jie Xu, 2021
  • J Exp Clin Cancer Res (2023, IF: 11.3), Jun Jie Xu, 2023
  • Sci China Life Sci (2022, IF: 10.372), Jun Jie Xu, 2022
  • Int J Cancer (2017, 2018, IF: 7.396), Jun Jie Xu, 2018
  • Theranostics (2020, IF: 11.6), Jun Jie Xu, 2020
  • Int J Biol Sci (2023, 2023, IF: 9.2), Jun Jie Xu, 2023
Liver Cancer Gallbladder Cancer Minimally Invasive Precision Diagnosis Drug Resistance Metastasis Translational Research Immune Microenvironment Metabolic Microenvironment Targeted Therapy

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.